Min Seong Kim1,2,*, Subeen Yoon3, Jiwoo Choi3, Yong Jun Kim3,4,5, Gabsang Lee1,2,6
1Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Korea
4Department of Pathology, College of Medicine, Kyung Hee University, Seoul, Korea
5KHU-KIST Department of Converging Science and Technology, Graduate School, Kyung Hee University, Seoul, Korea
6The Solomon Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Korea
4Department of Pathology, College of Medicine, Kyung Hee University, Seoul, Korea
5KHU-KIST Department of Converging Science and Technology, Graduate School, Kyung Hee University, Seoul, Korea
6The Solomon Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Correspondence to: Gabsang Lee
Department of Neurology, Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA
E-mail: glee48@jhmi.edu
Co-Correspondence to Yong Jun Kim
Department of Pathology, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea
E-mail: yjkim1@khu.ac.kr
*Current Affiliation: Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea
Department of Neurology, Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA
E-mail: glee48@jhmi.edu
Co-Correspondence to Yong Jun Kim
Department of Pathology, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea
E-mail: yjkim1@khu.ac.kr
*Current Affiliation: Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea
Received October 21, 2023; Revised February 15, 2024; Accepted February 16, 2024.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Abstract
- Parkinson’s disease (PD) is a neurodegenerative condition characterized by the loss of midbrain dopaminergic neurons, leading to motor symptoms. While current treatments provide limited relief, they don’t alter disease progression. Stem cell technology, involving patient-specific stem cell-derived neurons, offers a promising avenue for research and personalized regenerative therapies. This article reviews the potential of stem cell-based research in PD, summarizing ongoing efforts, their limitations, and introducing innovative research models. The integration of stem cell technology and advanced models promises to enhance our understanding and treatment strategies for PD.
- Keywords : Disease model, Parkinson disease, Stem cell therapy, Pathological mechanism
- November 2024, 17 (4)
Full Text(PDF) Free- Social Network Service
-
- Services
- Cited By Articles
-
CrossRef (2)
